Relatively Speaking
Early-Phase Oncology Trials Shaping the Future of Cancer Research
Tailored Artificial Intelligence (AI)
Controlling Polysorbate Degradation
From the “AI Pilot Graveyard” to Enterprise- Grade Impact
EDITORIAL SECTION
-
STRATEGY
Smarter Pharma
Quality management systems QMS are the backbone of pharmaceutical manufacturing ensuring safe products
-
RESEARCH DEVELOPMENT
Cytiva Laboratory capsule filters
Our singleuse selfcontained filtration solution
-
CLINICAL TRIALS
Why Clinical Trials Need Digital Endpoints
According Citeline the average success rate for bringing a Phase candidate to market has dropped to an alltime low of just
-
MANUFACTURING
Ensuring Quality and Compliance in Biopharma
Ensuring quality and regulatory compliance in the biopharmaceutical industry is critical to safeguarding product safety and efficacy
-
Information Technology
The Cost of Bad Data
Modern pharmaceutical research generates an unprecedented volume of information Data from genomic sequencing
-
Biopharma
Reimagining Global Biomanufacturing Capacity with Continuous and Modular Systems
Biotechnology is fueling the ongoing expansion of the global market for a broad array of goods
-
EXPERT Talk
Compliance to Competitive Advantage in Pharma Supply
Compliance gets you through an audit Resilience gets medicines to patients on the day something unexpected happens The DSCSAs enhanced requirements took effect November but real interoperability required three more rounds of accommodation phased implementation with the smalldispenser
Advisory Board
.webp)
KNOWLEDGE BANK
-
Articles
How to Mitigate Operational Risks in the Pharma Industry?
The operation of the pharmaceutical industry has significant risks with the most probable being operational risks These risks include supply chain interruption regulatory non compliance product defects technological disruption The development of strategies to avoid compromise in operations remains paramount not only in protecting the customers from harm or receiving
Greening the Pill: Pharmaceutical Companies Embrace Environmental Sustainability
In an age where global environmental sustainability is imperative various industries are reassessing their practices to diminish their ecological impact The pharmaceutical sector a crucial component of healthcare is no different This article explores the proactive steps taken by pharmaceutical companies to incorporate sustainability into manufacturing packaging and operations to lessen their envir...
Trustworthy AI in Drug Discovery: From Innovation to Regulatory Readiness
Artificial intelligence is entering a new phase in drug discovery After years of enthusiasm for predictive models generative chemistry and automated screening attention is shifting from what AI can generate to whether its outputs can be trusted
The Rise of Antibody-Drug Conjugates in European Cancer Treatment
For decades European oncologists faced an uncomfortable tradeoff Chemotherapy was powerful but indiscriminate damaging healthy tissue alongside tumour cells Targeted antibodies were precise but often lacked the firepower to eradicate aggressive disease on their own Antibodydrug conjugates resolve that tension by fusing both ideas into a single molecule
Medical Devices and Pharma: A Symbiotic Relationship for Improved Healthcare
The healthcare industry is continually evolving driven by technological advancements and innovative approaches to patient care Among the most significant developments is the symbiotic relationship between medical devices
Globalization of Pharma Operations: Opportunities and Challenges for European Companies
The globalization of pharmaceutical operations for European companies marks a pivotal strategic shift reflecting a historical evolution that has unfolded over time Understanding the context of this transformative journey is essential
-
Techno Trends
Alume Biosciences Secures FDA Breakthrough Therapy Designation for Bevonescein
Alume Biosciences has received Breakthrough Therapy Designation BTD from the US Food and Drug Administration FDA for bevonescein an investigational fluorescent drug being developed to support realtime nerve visualisation during head and neck surgery in adults Bevonescein is an intravenous fluorescent peptidedye conjugate that binds to nerve tissue
-
Projects
SK pharmteco Plans More Than US$200 Million Investment in Small Molecule and Peptide Manufacturing
SK pharmteco is planning a fiveyear investment of more than US million to expand and modernise its pharmaceutical development and manufacturing operations in the United States The programme will strengthen capabilities for small molecules and peptides while supporting a more
-
Research Insights
A drug repurposing screen reveals dopamine signaling as a candidate therapeutic pathway for PIGA-CDG
PIGACDG is a congenital disorder of glycosylation caused by pathogenic partial lossoffunction variants in the PIGA gene PIGA encodes an enzyme responsible for the catalytic transfer of Nacetylglucosamine
-
whitepaper
Post-Translational Modifications in Drug Discovery: From Molecular Regulation to Clinical Impact
For decades the central dogma of molecular biology has anchored our understanding of cellular function DNA to RNA to protein But this linear view is incomplete A growing body of evidence shows that much of biologys
TOP ARTICLES
-
1
Greening the Pill: Pharmaceutical Companies Embrace Environmental Sustainability
Debi Jones
Pharmaceutical companies are actively embracing environmental sustainability, implementing green chemistry in manufacturing, adopting renewable energy sources, and reducing single-use plastics through...
-
2
Trustworthy AI in Drug Discovery: From Innovation to Regulatory Readiness
Antonio Lavecchia
This article examines how AI-driven drug discovery is moving from experimental innovation toward trustworthy, regulatory-ready implementation. It discusses validation, interpretability, data integrity...
-
3
The Rise of Antibody-Drug Conjugates in European Cancer Treatment
Lakshmi
Antibody-drug conjugates (ADCs) are moving from niche, late-line options to front-line pillars of European oncology. By pairing the precision of monoclonal antibodies with highly potent cytotoxic payl...
-
4
Medical Devices and Pharma: A Symbiotic Relationship for Improved Healthcare
Kate Williamson
The symbiotic relationship between medical devices and pharmaceuticals revolutionizes healthcare by enhancing diagnostics, treatment, and disease management. This integration fosters personalized medi...
-
5
Globalization of Pharma Operations: Opportunities and Challenges for European Companies
Kate Williamson
The globalization of pharmaceutical operations presents European companies with opportunities for market expansion, access to talent, collaboration, cost optimization, and regulatory diversification....
press releases Read more...
Boehringer Ingelheim and SBP Group enter partnership to advance next-generation cancer therapies
Boehringer Ingelheim headquartered in Germany and Sino Biopharmaceutical Limited HK together with its subsidiaries SBP Group today announced a strategic multiprogram option and license agreement to advance potential nextgeneration cancer treatments based on antibodydrug conjugate ADC and Tcell engag...
Nxera Pharma Enters into Global License Agreement with AbbVie for NXE0033744, a Novel EP4 Receptor Agonist for Inflammatory Bowel Disease
Nxera Pharma Co Ltd announces that its subsidiary Nxera Pharma UK Ltd has entered into an exclusive global license agreement the Agreement with AbbVie Inc AbbVie for Nxeras EP agonist program including NXE a novel small molecule EP receptor agonist discovered
Oryzon announces authorization in Spain of VIVALDI, a collaborative clinical study with CETLAM to evaluate iadademstat in combination with standard-of-care therapy in high-risk newly-diagnosed AML subpopulations
Oryzon Genomics SA a clinicalstage biopharmaceutical company and global leader in epigenetics today announced that VIVALDI a Phase Ib pilot study sponsored by CETLAM Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplsicas has been authorized in Spain
Aarvik Therapeutics Announces Milestone Achievement, Partnership Update, and Presentations on MUTTA™ and AQUALINK™ Platforms at the 17th Annual WADC Conference
Aarvik Therapeutics Aarvik an innovative ADCfocused biotechnology company dedicated to engineering precision medicines for cancer therapy is pleased to announce important updates to its partnership efforts Dosing of the first patient in a Phase trial in the US for AVPADC
Events Read more...
03 - 05
Nov 202610th Dermatology Drug Development
Boston, Massachusetts at The C...
04 - 05
Nov 2026Advanced Therapies USA
Hynes Convention Center, Bosto...
05 - 05
Nov 2026PDA Contamination Control Strategy Workshop
Sheraton Grand Incheon Hotel,...
09 - 11
Nov 202611th Microbiome Movement USA Summit
The Colonnade Hotel, Boston, M...
10 - 11
Nov 2026Extractables & Leachables Europe
Parkhotel Schӧnbrunn, Vienna,...
10 - 10
Nov 2026Women in AI
Real Chemistry, 2nd Floor, Lon...
11 - 13
Nov 2026Frontiers in Cancer Science 2026
One Farrer Hotel,1 Farrer Park...
11 - 12
Nov 2026Medical Device Project and Portfolio Management
Chicago, IL, USA
LATEST NEWS Read more...
Breakthrough Therapy Designation granted by the FDA for daridorexant in pediatric insomnia disorder
Idorsia Ltd announced that the US Food and Drug Administration FDA has granted Breakthrough Therapy Designation to daridorexant for the treatment of insomnia disorder in patients to
Evestia Clinical Acquires Emtex Life Science to Further Enhance its Global Full-Service Clinical Research Capabilities
Evestia Clinical a leading independent global specialist Contract Research Organization CRO today announced the acquisition of Emtex Life Science Emtex a specialist regulatory medical writing company headquartered in Belgium The acquisition strengthens Evestia
UroGen Announces First Patient Dosed in Phase 1 Trial of UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer
UroGen Pharma Ltd a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers today announced that the first patient was dosed with UGN a nextgeneration investigational oncolytic virus The Phase trial will evaluate the safety tolera...
Graviton BioScience and CinRx Pharma Form CinRock Pharma to Advance ROCK2-Targeted Therapies for Cardiovascular Disease
Graviton BioScience Corporation Graviton and CinRx Pharma CinRx today announced the formation of CinRock Pharma CinRock a jointly governed biopharmaceutical company established to accelerate the development of novel ROCKtargeted therapies for patients with cardiovascular diseases
Pretzel Therapeutics Receives UK Regulatory Authorization to Advance PX578 Into Clinical Development in Patients for the Treatment of POLG-Mediated Primary Mitochondrial Disorders
Pretzel Therapeutics Inc a clinicalstage biotechnology company advancing a new class of medicines designed to restore mitochondrial function improve cellular energetics and impede disease progression across a range of neurological and rare diseases today announced that the Medicines and Healthcare p...
TME Pharma Signs Binding Exclusive Negotiation Agreement with Japanese TMS Co., Ltd.
TME Pharma NV Euronext Growth Paris ALTME a biotechcompany with clinical assets for brain cancer and eye diseases is pleased to announce a significant next step in the strategic options for its leading oncology asset NOXA olaptesed pegol
